Literature DB >> 3663464

Infusion-rate independent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM).

R Raijmakers1, P Speth, T de Witte, P Linssen, J Wessels, C Haanen.   

Abstract

The effect of adriamycin (ADM) infusion-rate on cellular ADM concentrations and on clonogenicity of human haematopoietic cells was studied in vivo and in vitro. In patients an ADM dose of 30 mg m-2 was administered as a bolus injection, or as a 4 h or a 24 h infusion. In vitro the effect of ADM on clonogenic cell growth was determined after exposure during 5 min, 2 h and 24 h of human bone marrow cells to increasing ADM concentrations. ADM showed rapid intracellular accumulation, to levels 100-fold the plasma concentration in vivo or the incubation medium concentration in the in vitro experiments. After a bolus injection or 5 min exposure only approximately 10% of the cellular peak ADM was retained after elimination of the drug from the plasma or the incubation medium. Ninety percent of the ADM was apparently 'loosely' bound. After 4 h and 24 h constant-rate infusions and also after 2 h and 24 h incubations in vitro, the cells accumulated ADM gradually, and the subsequent washing-out of the cellular ADM was substantially less, most of the ADM being 'tightly' bound. Despite these different patterns of uptake and retention after in vivo short- and long-lasting infusion of the same total dose, the 'tightly-bound' cellular ADM concentrations were the same. Moreover, comparable cellular ADM concentrations, retained after efflux of the 'loosely-bound' cellular ADM fraction were equally cytotoxic to normal human clonogenic cells. Short-lasting cellular peak ADM concentrations which occur after a bolus injection or after short exposure to high ADM concentrations are not essential for the cytotoxic effect, in contrast to the retained, 'tightly-bound' cellular ADM levels.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663464      PMCID: PMC2002152          DOI: 10.1038/bjc.1987.168

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Colony stimulating factor augmentation in human placental conditioned medium.

Authors:  D S Verma; G Spitzer; M Beran; A R Zander; K B McCredie; K A Dicke
Journal:  Exp Hematol       Date:  1980-08       Impact factor: 3.084

2.  Rapid quantitative determination of four anthracyclines and their main metabolites in human nucleated haematopoietic cells.

Authors:  P A Speth; P C Linssen; J B Boezeman; J M Wessels; C Haanen
Journal:  J Chromatogr       Date:  1986-04-25

3.  Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells.

Authors:  T Skovsgaard
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

4.  Clinical evaluation of long-term, continuous-infusion doxorubicin.

Authors:  M B Garnick; G R Weiss; G D Steele; M Israel; D Schade; M J Sack; E Frei
Journal:  Cancer Treat Rep       Date:  1983-02

5.  Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin.

Authors:  B Andersson; M Beran; C Peterson; B Tribukait
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

6.  Cellular pharmacokinetics of doxorubicin in cultured mouse sarcoma cells originating from autochthonous tumors.

Authors:  T Nguyen-Ngoc; P Vrignaud; J Robert
Journal:  Oncology       Date:  1984       Impact factor: 2.935

7.  Daunomycin administered by continuous intravenous infusion is effective in the treatment of acute nonlymphocytic leukaemia.

Authors:  J P Lewis; F J Meyers; L Tanaka
Journal:  Br J Haematol       Date:  1985-10       Impact factor: 6.998

8.  Uptake of adriamycin by human leukemic cells as measured by flow cytometry.

Authors:  H D Preisler; A Raza
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

9.  Quantitation of anthracyclines in human hematopoietic cell subpopulations by flow cytometry correlated with high pressure liquid chromatography.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cytometry       Date:  1985-03

10.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.

Authors:  S S Legha; R S Benjamin; B Mackay; M Ewer; S Wallace; M Valdivieso; S L Rasmussen; G R Blumenschein; E J Freireich
Journal:  Ann Intern Med       Date:  1982-02       Impact factor: 25.391

View more
  2 in total

Review 1.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

Review 2.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.